Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | BRAF | P15056 | 18/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545358 | 0.92 | BRAF (0.59) | RAF1BRAFEGFRLCKRET | |
| SCHEMBL545995 | 0.92 | BRAF (0.52) | RAF1EPHX2BRAFEGFRLCK | |
| SCHEMBL545630 | 0.90 | BRAF (0.53) | RAF1BRAFEGFRLCKRET | |
| SCHEMBL5429595 | 0.90 | BRAF (0.51) | RAF1EPHX2BRAFEGFRLCK | |
| SCHEMBL545462 | 0.90 | BRAF (0.52) | RAF1BRAFEGFRLCKRET | |
| SCHEMBL546007 | 0.89 | BRAF (0.51) | RAF1BRAFEGFRLCKRET | |
| SCHEMBL546005 | 0.89 | BRAF (0.53) | RAF1BRAFEGFRLCKRET | |
| SCHEMBL545680 | 0.89 | BRAF (0.51) | RAF1BRAFEGFRLCKRET | |
| SCHEMBL546161 | 0.89 | BRAF (0.51) | RAF1BRAFEGFRLCKRET | |
| SCHEMBL545415 | 0.89 | BRAF (0.54) | RAF1BRAFKDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | RAF1 198/4885EPHX2 2205/4885BRAF 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.